These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25065013)

  • 21. [Evidence-based therapy of systemic sclerosis].
    Genth E
    Z Rheumatol; 2001 Dec; 60(6):464-8. PubMed ID: 11826742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scleroderma and related disorders: therapeutic aspects.
    Denton CP; Black CM
    Baillieres Best Pract Res Clin Rheumatol; 2000 Mar; 14(1):17-35. PubMed ID: 10882212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
    Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic sclerosis: an update.
    Varga J
    Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.
    Walker KM; Pope J; ;
    Semin Arthritis Rheum; 2012 Aug; 42(1):42-55. PubMed ID: 22464314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis.
    Allanore Y; Distler O; Matucci-Cerinic M; Denton CP
    Arthritis Rheumatol; 2018 Feb; 70(2):162-170. PubMed ID: 29145709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting vascular disease in systemic sclerosis.
    Kowal-Bielecka O
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy.
    Strange G; Nash P
    Int J Rheum Dis; 2009 Sep; 12(3):192-206. PubMed ID: 20374346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
    Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
    Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Sclerosis and Pulmonary Disease.
    Ngo K
    Adv Exp Med Biol; 2021; 1303():173-182. PubMed ID: 33788193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic sclerosis: hypothesis-driven treatment strategies.
    Charles C; Clements P; Furst DE
    Lancet; 2006 May; 367(9523):1683-91. PubMed ID: 16714190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The contemporary management of systemic sclerosis.
    Eldoma M; Pope J
    Expert Rev Clin Immunol; 2018 Jul; 14(7):573-582. PubMed ID: 29874475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany].
    Juche A; Siegert E; Mueller-Ladner U; Riemekasten G; Günther C; Kötter I; Henes J; Blank N; Voll RE; Ehrchen J; Schmalzing M; Susok L; Schmeiser T; Sunderkoetter C; Distler J; Worm M; Kreuter A; Horváth ON; Schön MP; Korsten P; Zeidler G; Pfeiffer C; Krieg T; Hunzelmann N; Moinzadeh P
    Z Rheumatol; 2020 Dec; 79(10):1057-1066. PubMed ID: 32040755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
    Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.
    Ghizzoni C; Sebastiani M; Manfredi A; Campomori F; Colaci M; Giuggioli D; Ferri C
    Microvasc Res; 2015 May; 99():92-5. PubMed ID: 25842153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis.
    Taniguchi T; Miyagawa T; Toyama S; Yamashita T; Nakamura K; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sato S; Asano Y
    Exp Dermatol; 2018 Sep; 27(9):1030-1037. PubMed ID: 29947047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.